Sinovac Biotech revamps controversial take-private

Beset by long-running activist investor concerns and legal issues – not least bribery concerns – the biopharmaceutical products manufacturer has upped its de-listing offer.

Sinovac Biotech revamps controversial take-private

Sinovac Biotech has upped its offer to de-list from Nasdaq almost 17 months after it first tried to go private, in a deal that values the firm at around $401.8 million. But it could still have its work cut out to get the deal done given ongoing pricing disputes and bribery concerns. 

According to a filing to the US Securities and Exchange Commission SEC on Monday, parent entity Sinovac Cayman Limited will acquire the...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES